Ser672

Site Information
APLGPPVsPPHVSTF SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 56668652

In vivo Characterization
Methods used to characterize site in vivo:	[32P] ATP in vitro ( 2 ) , immunoprecipitation ( 1 , 2 ) , mass spectrometry ( 1 , 3 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 2 )
Disease tissue studied:	breast cancer ( 1 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 ) , liver cancer ( 2 ) , hepatocellular carcinoma ( 2 )
Relevant cell line - cell type - tissue:	breast ( 3 ) , E.coli (bacterial) ( 2 ) , HEK293T (epithelial) ( 1 ) , HeLa (cervical) ( 2 ) , Huh7 (hepatic) ( 2 ) , MDA-MB-231 (breast cell) ( 1 )

Downstream Regulation
Effects of modification on HIF2A:	intracellular localization ( 2 ) , molecular association, regulation ( 2 )
Effects of modification on biological processes:	transcription, induced ( 2 )
Inhibit interaction with:	Exportin-1 (human) ( 2 )

References
1	Guillen-Quispe YN, et al. (2023) Oxygen-independent stabilization of HIF-2α in breast cancer through direct interaction with peptidyl-prolyl cis-trans isomerase NIMA-interacting 1. Free Radic Biol Med 207, 296-307 37473874 Curated Info
2	Gkotinakou IM, Befani C, Simos G, Liakos P (2019) ERK1/2 phosphorylates HIF-2α and regulates its activity by controlling its CRM1-dependent nuclear shuttling. J Cell Sci 132 30962349 Curated Info
3	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info